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MaGroundbreaking advances in stem cell research have led to techniques for the creation of human cardiomyocytes from
cells procured from a variety of sources, including a simple skin biopsy. Since the advent of this technology, most
research has focused on utilizing these cells for therapeutic purposes. However, recent studies have demonstrated that
stem cell–derived cardiomyocytes generated from patients with inherited cardiovascular disorders recapitulate key
phenotypic features of disease in vitro. Furthermore, these cells can be maintained in culture for prolonged periods of
time and used for extensive biochemical and physiological analysis. By serving as models of inherited cardiac disorders,
these systems have the potential to fundamentally change the manner in which cardiovascular disease is studied and new
therapies are developed. (J Am Coll Cardiol 2014;64:512–9) © 2014 by the American College of Cardiology Foundation.T he ability to translate basic scientiﬁc discov-ery into clinically-useful technology requiresmodel systems that faithfully reﬂect the
pathophysiology of human disease. Although animal
models have contributed greatly to the study of car-
diovascular disorders, experimental ﬁndings in these
models often correlate poorly with outcomes in hu-
man studies (1–4). Ideally, the study of cardiac dis-
eases would involve cardiomyocytes (CMs) obtained
directly from patients, but difﬁculties in procuring
and maintaining primary CMs in culture limits exper-
imentation with human cardiac tissue.
Given the technical difﬁculties of working with
direct human cardiac tissue, an enticing alternative
for studying cardiovascular diseases (CVDs) has
emerged: CMs generated from pluripotent stem cells
(PSCs) (Central Illustration). This approach provides a
new means for studying a wide spectrum of human
diseases previously impervious to rigorous scientiﬁc
investigation. Herein, we review how PSC-CMs are
created as well as the various CVDs that have been
studied using these systems. We then describe how
PSC-CMs can be utilized for both drug discovery andm the *Department of Medicine, Division of Cardiology, University of C
ul L. Foster School of Medicine, Texas Tech University Health Sciences C
y have no relationships relevant to the contents of this paper to disclose
nuscript received April 2, 2014; revised manuscript received May 27, 201toxicity studies, and we comment on the limitations
of this potentially disruptive technology.
GENERATION OF CMs FROM PSCs
Mouse embryonic stem cells (ESCs) were ﬁrst estab-
lished in culture in 1981 by Evans et al. (5); 7 years
later, Thomson et al. (6) developed the ﬁrst human
embryonic stem cell (hESC) line. In 2006, Takahashi
and Yamanaka (7) demonstrated in mice that adult
skin ﬁbroblasts could be reprogrammed into ESC-like
cells by using a retroviral vector to force the expres-
sion of the original 4 transcription factors: Oct3/4,
Sox2, Klf4, and c-Myc. Further research reproduced
these ﬁndings using human ﬁbroblasts and showed
that these cells, known as human-induced pluripo-
tent stem cells (hiPSC), were capable of self-renewal,
could be maintained in an undifferentiated state for
extended periods, and could give rise to all somatic
cell types (8–13).
Investigators employ several techniques to pro-
duce CMs from hESCs and hiPSCs (hereafter abbrevi-
ated as hESC-CMs and hiPSC-CMs when speciﬁcallyalifornia San Diego, San Diego, California; and the
enter, El Paso, Texas. All authors have reported that
.
4, accepted May 28, 2014.
ABB R E V I A T I O N S
AND ACRONYMS
APD = action potential
duration
ARVD/C = arrhythmogenic
right ventricular dysplasia/
cardiomyopathy
CM = cardiomyocyte
CVD = cardiovascular disease
DCM = dilated cardiomyopathy
ESC = embryonic stem cell
HCM = hypertrophic
cardiomyopathy
hiPSC = human-induced
pluripotent stem cell
hPSC = human pluripotent
stem cell
LQTS = long QT syndrome
= pluripotent stem cell
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513referring to CM generation). The ﬁrst widely-used
method for developing PSC-CMs involved coculturing
hESCs with the mouse endodermal cell line END-2,
which stimulates differentiation toward a CM-like
phenotype (14). However, this technique proved rela-
tively inefﬁcient and remains infrequently used in
laboratory practice (15–18).
More commonly, human pluripotent stem cell
(hPSC)-CMs are generated by either the “embryoid
body” or monolayer techniques. With the former,
hPSCs are removed from conditions supporting plu-
ripotency and are suspended in droplets or plated on
low-adherency plates. This promotes the formation of
cell aggregates, termed embryoid bodies, which
spontaneously differentiate into all 3 germ layers (19).
Some of these differentiated cells will develop a “car-
diomyocyte-like” phenotype and contract spontane-
ously. Although this technique demonstrated limited
initial success (20,21), the stepwise addition and inhi-
bition of signaling factors that replicate known steps in
cardiac development has greatly improved efﬁciency
(22–27). Current protocols typically result in the pro-
duction of >70% to 90% hPSC-CMs. Further modiﬁca-
tions, such as growing hPSCs as a monolayer, have
allowed researchers to generate vast quantities of
these cells entirely in chemically-deﬁned media
(28–32).
LIMITATIONS OF hiPSCS. Although hESCs were the
ﬁrst cells differentiated into CMs, the revolutionary
discovery that adult cells could be reprogrammed to a
pluripotent state greatly expanded the research uses
for human stem cells. Most importantly, hiPSCs
contain the complete genetic information of theCENTRAL ILLUSTRATION The Generation and Application of hiPS
Cardiomyocytes can be generated from patient-speciﬁc induced pluripot
Activin, Wnt/B-catenin, and BMP signaling pathways. Human induced p
platform for modeling of cardiovascular disorders, drug screening, rege
CVD ¼ cardiovascular disease.individual from which they derive, providing
the possibility of recreating and studying
genetically-based diseases in vitro. Yet,
despite their vast theoretical potential, cur-
rent hiPSC systems have key limitations that
restrict their widespread application to
translational research.
At present, most laboratories employ pro-
tocols that utilize retroviral vectors to repro-
gram adult cells to a pluripotent state.
Although reprogramming silences the tran-
scription of viral transgenes, there is an
inherent risk that the use of retroviral
expression systems can cause events that
could alter the host-cell phenotype, such as
viral transgene reactivation, insertional
mutagenesis, and host-cell gene removal.
hiPSCs produced by these systems require
intensive screening to exclude such events.Current differentiation protocols produce admix-
tures of cells that have pacemaker-, atrial-, and
ventricular-like phenotypes (33). Although research is
ongoing to develop protocols that generate only the
desired cell type, currently it is difﬁcult to isolate
homogenous cell populations. Of greater concern,
however, is that gene expression patterns of hPSC-
CMs more closely resemble fetal cardiac tissue than
adult cells and that they act mechanically and elec-
trophysiologically like immature CMs (34–37).
Compared with adult CMs, hPSC-CMs are smaller
and circular in morphology, with greater myoﬁbril
disorganization and a shorter sarcomere length
(13,14,37,38). These differences alter cell membrane
PSCC-CMs
ent stem cells through stage-speciﬁc activation and inhibition of the
luripotent stem cell–derived cardiomyocytes (hiPSC-CMs) provide a
nerative medicine, and many other experimental applications.
TABLE 1 Summary of Published hiPSC Models of Cardiovascular Disease
First Author (Ref. #) Year Summary
Arrhythmogenic
right ventricular
dysplasia/cardiomyopathy
Caspi et al. (59) 2013 Heterozygous frameshift mutation in PKP2 (A324fs335X)
Kim et al. (57) 2013 Homozygous silent mutation in PKP2 resulting
in cryptic splicing (c.2484C>T)
Ma et al. (58) 2013 Heterozygous missense mutation in PKP2 (L614P)
Catecholaminergic
polymorphic ventricular
tachycardia
Zhang et al. (62) 2013 Heterozygous missense mutation in RYR2 (F2483I)
Di Pasquale et al. (65) 2013 Heterozygous missense mutation in RYR2 (E2311D)
Novak et al. (66) 2012 Homozygous missense mutation in CASQ2 (D307H)
Kajula et al. (64) 2012 Heterozygous missense mutation in RYR2 (P2328S)
Itzhaki et al. (63) 2012 Heterozygous missense mutation in RYR2 (M4109R)
Jung et al. (61) 2012 Heterozygous missense mutation in RYR2 (S406L)
Fatima et al. (60) 2011 Heterozygous missense mutation in RYR2 (F2483I)
Dilated cardiomyopathy
Siu et al. (45) 2012 Heterozygous nonsense mutation in LMNA (R225X)
Sun et al. (46) 2012 Heterozygous missense mutation in TNNT2 (R173W)
Ho et al. (44) 2011 Heterozygous frameshift mutation in LMNA (S17fs40X)
Hypertrophic cardiomyopathy
Lan et al. (43) 2013 Heterozygous missense mutation in MYH7 (R663H)
LEOPARD syndrome
Carvajal-Vergara et al. (42) 2010 Heterozygous missense mutation in PTPN11 (T468M)
Long QT syndrome
Matsa et al. (52) 2013 Heterozygous missense mutation in KCNH2 (A561T)
Ma et al. (55) 2013 Heterozygous missense mutation in SCN5A (V1763M)
Bellin et al. (53) 2013 Heterozygous missense mutation in KCNH2 (N996I)
Terrenoire et al. (54) 2012 Heterozygous missense mutation in SCN5A (F1473C)
and polymorphism in KCNH2 (K897T)
Egashira et al. (38) 2012 Heterozygous deletion mutation in KCNQ1 (P631fs/33)
Lahti et al. (51) 2012 Heterozygous missense mutation in KCNH2 (R176W)
Itzhaki et al. (49) 2011 Heterozygous missense mutation in KCNH2 (A614V)
Matsa et al. (50) 2011 Heterozygous missense mutation in KCNH2 (A561T)
Yazawa et al. (56) 2011 Heterozygous missense mutation in CACNA1C (G406R)
Moretti et al. (47) 2010 Heterozygous missense mutation in KCNQ1 (R190Q)
Pompe syndrome
Huang et al. (66) 2011 Speciﬁc mutations not published
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514capacitance, the rate of action potential depolariza-
tion, and maximum contractile force of hPSC-CMs
(37). These hPSC-CMs also possess uniform distribu-
tion of the gap junction protein connexin 43 on
the cell membrane (34,39)—which in adult cells is
concentrated at the intercalated discs—and, like fetal
CMs, they lack well-developed T-tubule (or trans-
verse tubule) structures (38,40,41). Developing new
techniques to make hPSC-CMs more “mature” will be
critical for the technology to reach its full potential.
Despite these limitations, hiPSCs represent a new
frontier in translational research, bringing the idea of
recreating diseases “in the dish” closer to reality.
Already, several genetically-based CVDs have been
studied using hiPSCs. These models offer new in-
sights into the molecular mechanisms underlyingthese diseases and hold exciting potential for the
development of new diagnostic, prognostic, and
therapeutic tools. In the following text, we review
cardiac disease models that have been published and
the potential for these models to advance trans-
lational research (Table 1).
CARDIOVASCULAR DISEASE MODELS
THE LEOPARD SYNDROME. Investigators created the
ﬁrst hiPSC model of a CVD using skin ﬁbroblasts from
a patient with LEOPARD (lentigines, electrocardio-
gram conduction abnormalities, ocular hypertelorism,
pulmonic stenosis, abnormal genitalia, retardation of
growth, and sensorineural deafness) syndrome, an
autosomal-dominant disorder caused by a mutation
in the PTPN11 gene encoding the protein-tyrosine
phosphatase Shp2 that also results in myocardial hy-
pertrophy. Compared with control subjects, LEOPARD
hiPSC-CMs exhibit an increased median surface area
and gene expression proﬁles consistent with HCM.
Investigators have now demonstrated for the ﬁrst
time that hiPSC-CMs retain key phenotypic features of
the patients from which they were derived (42).
HYPERTROPHIC CARDIOMYOPATHY. Characterized
by an abnormal thickening of the ventricular wall,
HCM can predispose affected individuals to aortic
outﬂow obstruction, heart failure, and malignant
ventricular arrhythmias. To better understand its
pathophysiology, Lan et al. (43) recently developed a
model of HCM from 5 related patients with a missense
mutation in the beta-myosin heavy chain gene
(MYH7). The HCM hiPSC-CMs produced were enlarged
and multinucleated and had increased sarcomeric
disorganization. Genetic analysis performed on hiPSC-
CMs 40 days after cardiac induction showed an up-
regulation of hypertrophy-related genes. They also
exhibited arrhythmogenic waveforms and irregular
Ca2þ transients. At 30 days post-induction, cytosolic
Ca2þ concentration was approximately 30% higher in
HCM hiPSC-CMs versus control subjects. Caffeine
stimulation in diseased hiPSC-CMs caused smaller
Ca2þ releases from the sarcoplasmic reticulum into the
cytoplasm than in control subjects, suggesting that
there is worse contractile function. Administration of
calcineurin inhibitors, which block hypertrophy-
related signaling pathways, reduced hypertrophy in
HCM hiPSC-CMs. Stimulation of diseased hiPSC-CMs
with isoproterenol caused a 2-fold increase in cell
size and exacerbated irregular Ca2þ transients; coad-
ministration of a beta-blocker abrogated these effects.
Overall, these ﬁndings implicated abnormal Ca2þ
handling as the central mechanism in the pathophys-
iology of HCM (43).
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515FAMILIAL DILATED CARDIOMYOPATHY. A leading
cause of nonischemic heart failure, familial dilated
cardiomyopathy (DCM) results in ventricular dilation
and systolic dysfunction. Two groups have pub-
lished hiPSC models of DCM with mutations in the
lamin A/C gene, which encodes 2 isoforms of A-type
lamins found in the nuclear lamina. By immunoﬂu-
orescence, DCM hiPSCs displayed signiﬁcant nuclear
abnormalities; electron microscopy showed nuclear
pore dilation, heterochromatin aggregation, and
mitochondrial accumulation around the nuclear en-
velope (44). Electrical stimulation of DCM hiPSC-
CMs increased nuclear senescence and apoptosis
(44,45). Further investigation implicated the acti-
vation of MEK1, a component of the mitogen-
activated protein kinase signaling pathway, as a
key mediator in these events. Applying a MEK1 in-
hibitor diminished the apoptotic effects of electrical
stimulation (45).
Sun et al. (46) published an hiPSC model of DCM
from patients with a mutation in the troponin T type 2
gene (TNNT2). Compared with control subjects, DCM
hiPSC-CMs demonstrated an abnormal distribution of
sarcomeric alpha-actinin and underdeveloped mito-
chondria and sarcoplasmic reticulum. DCM hiPSC-
CMs also had smaller cytosolic Ca2þ transients and
weaker contraction as measured by atomic force mi-
croscopy. Treatment of DCM embryoid bodies with
norepinephrine eliminated spontaneous contractions
and increased sarcomeric disorganization and myo-
ﬁlament degeneration. Mechanical cell stretching
produced similar results. Metoprolol treatment
decreased the number of cells with disorganized
alpha-actinin staining, and overexpression of Serca2
increased Ca2þ transients and strengthened measured
contractions. The investigators also identiﬁed 191
genes with differing expression levels in diseased
hiPSC-CMs compared with control subjects, several of
which had not been previously linked to DCM and
may be future targets for investigation.
LONG QT SYNDROME. Long QT syndrome (LQTS) is
characterized by prolonged cardiac repolarization
that can result in fatal ventricular arrhythmias. More
than a dozen different types of inherited LQTS have
been described, and hiPSCs have been used to study
LQTS types 1, 2, 3, and 8. Long QT syndrome type 1
(LQTS1) is caused by a mutation in the KCNQ1 gene,
which encodes a voltage-gated potassium channel,
Kv7.1, responsible for the slow component of the
delayed rectiﬁer potassium current. Moretti et al. (47)
and Egashira et al. (48) showed that LQTS1 hiPSC-CMs
had prolonged action potential duration (APD) on
patch-clamping and a prolonged ﬁeld potential
duration on multielectrode array (MEA) analysis,ﬁndings that correlate with QT prolongation on elec-
trocardiogram. Immunohistological testing showed
that, in LQTS1 hiPSC-CMs, the diseased KCNQ1 pro-
tein localized to the endoplasmic reticulum rather
than the cell surface (47,48). Treatment with an in-
hibitor of the fast component of the delayed rectiﬁer
potassium current (IKr) induced polymorphic ven-
tricular tachycardia (VT)-like arrhythmias in LQTS1
hiPSC-CMs (48). Furthermore, isoproterenol stimula-
tion caused VT-like arrhythmic events in diseased
hiPSC-CMs, which could be ameliorated by propran-
olol pre-treatment (47,48).
Long QT syndrome type 2 (LQTS2) results from a
mutation in the KCNH2 gene encoding the alpha-
subunit, Kv11.1 of the IKr or human ether-à-go-go
related gene (hERG) channel. LQTS2 hiPSC-CMs
exhibited prolonged APD and reduced repolarization
compared with control subjects. MEA mapping
demonstrated early afterdepolarizations (EADs) that
gave rise to premature beats (49–53). Administration
of beta-adrenergic agonists induced EADs, which
then responded to beta-adrenergic blockers (50).
Treatment with nifedipine and pinacidil, for example,
completely eliminated EADs and triggered beats, but
stopped contraction in some embryoid bodies.
Ranolazine demonstrated antiarrhythmic effects, but
did not alter APD in these cells (49).
Type 3 long QT syndrome (LQTS3) springs from
persistent Naþ inﬂux during depolarization due to
mutations in the SCN5A gene, which encodes the
Nav1.5 sodium channel. Terrenoire et al. (54) devel-
oped an hiPSC model from a patient with an SCN5A
mutation and a polymorphism in KCNH2. They
demonstrated that the Naþ channel defect was the
causal mutation in this patient with complicated ge-
netics. Mexiletine treatment improved Naþ channel
function, but concomitant inhibition of IKr limited its
use. Ma et al. (55) also developed an hiPSC-CM model
of LQTS3 and showed that diseased CMs had a pro-
longed APD, correlating clinically with QT prolonga-
tion on electrocardiogram.
Yazawa et al. (56) modeled Timothy syndrome, a
rare autosomal dominant disorder caused by a muta-
tion in the CACNA1C gene encoding the voltage-
dependent L-type calcium channel, Cav1.2., which is
characterized by long ST syndrome type 8 (LQTS8),
autism, immunodeﬁciency, and syndactyly. Com-
pared with control subjects, LQTS8 hiPSC-CMs con-
tractedmore slowly and irregularly. Cav1.2 Caþ current
in diseased hiPSC-CMs signiﬁcantly reduced voltage-
dependent inactivation, and ventricular-like LQTS8
hiPSC-CMs had APDs 3 times longer than control sub-
jects. Numerous depolarizing events failed to trigger a
full action potential in the LQTS8 hiPSC-CMs,
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derlie the disease (56).
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA/
CARDIOMYOPATHY. Characterized by ﬁbrofatty re-
placement of CMs in the right ventricle, arrhythmo-
genic right ventricular dysplasia/cardiomyopathy
(ARVD/C) results from mutations in the cardiac des-
mosome. Kim et al. (57) developed a model of ARVD/C
with hiPSC-CMs from 2 patients with homozygous
and heterozygous mutations in the plakophilin-2
gene (PKP2). Treatment with adipogenic factors
increased expression of peroxisome proliferator-
activated receptor–alpha, a transcriptional regulator
of fatty acid metabolism. Additional administration of
activators of the peroxisome proliferator-activated
receptor–gamma pathway, which may be hyper-
activated in ARVD/C patients, increased lipogenesis
and apoptosis and further shifted energy metabolism
toward glucose utilization, an effect also seen in end-
stage heart failure (57).
Additionally, Ma et al. (58) and Caspi et al. (59)
published hiPSC models of ARVD/C from patients
with heterozygous PKP2 mutations. ARVD/C hiPSC-
CMs demonstrated reduced transcription and immu-
noﬂuorescent staining of PKP2 and plakoglobin as
well as reduced expression of gap-junction proteins
(58,59). Transmission electron microscopy showed
darker lipid drops and increased desmosomal abnor-
malities in diseased hiPSC-CMs (58,59). Lipogenic
stress applied to ARVD/C hiPSC-CMs resulted in
extensive lipid droplet accumulation (59).
CATECHOLAMINERGIC POLYMORPHIC VT. A stress-
induced ventricular arrhythmia, catecholaminergic
polymorphic ventricular tachycardia (CPVT) can pro-
duce polymorphic VT, syncope, and sudden cardiac
death. Type 1 (CPVT1) is caused by an autosomal
dominant mutation in the cardiac ryanodine receptor
gene (RYR2), type 2 (CPVT2) by an autosomal reces-
sive mutation in the calsequestrin gene. Both types
trigger aberrant diastolic Ca2þ release from the
sarcoplasmic reticulum, and several hiPSC models
have been developed for both conditions.
Under basal conditions, control and CPVT1 hiPSC-
CMs had similar resting, systolic, and diastolic
sarcoplasmic reticulum Ca2þ concentrations (60,61).
But, diseased hiPSC-CMs showed higher amplitudes
and longer durations of spontaneous local Ca2þ
release. Ca2þ release from internal stores also con-
tinued after repolarization in diseased hiPSC-CMs.
These ﬁndings were consistent with aberrant sarco-
plasmic reticulum Ca2þ release. Electrical pacing and
beta-adrenergic stimulation exacerbated Ca2þ han-
dling abnormalities in CPVT1 hiPSC-CMs and resultedin arrhythmogenic abnormalities on electrophysio-
logical testing (60–64).
Several groups have analyzed various drugs to
further elucidate properties of CPVT1 and eval-
uate treatment options. Propranolol and ﬂecainide
reversed the observed abnormalities induced by
stress-like stimulation (63), whereas dantrolene, an
inhibitor of the skeletal ryanodine receptor, restored
normal Ca2þ spark properties and abolished triggered
arrhythmias in diseased hiPSC-CMs (61). CPVT1
hiPSC-CMs treated with KN-93, a calcium/calmod-
ulin-dependent serine-threonine protein kinase II
inhibitor, demonstrated blunting of isoproterenol-
induced electrical abnormalities. Treatment also
stabilized calcium activation, resulting in a single
initiation site in a beating cell cluster (65).
CPVT2 was studied with an hiPSC model derived
from 2 family members with mutations in the calse-
questrin gene. No differences were seen in gene
expression or calsequestrin protein levels in diseased
hiPSC-CMs compared with control subjects, but
transmission electron microscopy showed large
glycogen deposits, lipid droplets, roughened endo-
plasmic reticulum, reduced number of caveolae, and
abnormally dilated and fragmented sarcoplasmic re-
ticulum cisternae in CPVT2 hiPSCs (66).
POMPE DISEASE. This autosomal recessive disorder
is caused by mutations in the acid alpha glucosidase
gene (GAA), a lysosomal glycogen-degrading enzyme.
Huang et al. (67) developed an hiPSC model of Pompe
disease with a doxycycline-inducible expression of
acid alpha glucosidase. Pompe hiPSC-CMs demon-
strated depressed acid alpha-glucosidase activity and
increased glycogen content, which was reversed with
doxycycline treatment.
Additionally, diseased hiPSC-CMs produced lower
oxygen consumption rates and lower extracellular
acidiﬁcation rates, suggestive of mitochondrial dys-
function. Human recombinant acid alpha-glucosidase
and an autophagy inhibitor signiﬁcantly reduced
glycogen content in Pompe hiPSC-CMs. By comparing
the expression of 16 genes related to glycogen metab-
olism and lysosomal and mitochondrial function in
doxycycline-treated and untreated cells, they identi-
ﬁed 6 genes as potential targets for in vivo drug testing.
CLINICAL APPLICATIONS
Recent advances in PSC technology are changing the
landscape of translational research. CVD models
based on this technology have the potential to help
dissect the molecular pathways responsible for dis-
ease pathology and facilitate the rational design of
targeted drugs toward these pathways.
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517Screening for drug toxicities represents an area of
research potentially wide open to the use of hPSC
models. More than one-third of medication with-
drawals from 1990 to 2006 were related to cardiotox-
icity (68). Currently, all developmental compounds
must pass an hERG screen for QT-prolonging effects
prior to clinical-use approval, but this screen relies on
the use of nonhuman, noncardiac cells overexpressing
a single ion channel. The drug alfuzosin famously
passed hERG testing, but was later found to cause QT
prolongation when used clinically. It was subse-
quently determined that alfuzosin does not bind
the hERG channel, instead prolonging the QT interval
through modulations in sodium currents (69), high-
lighting a critical weakness of this screening modality.
Equally worrisome is that verapamil, a widely-used
medication with no clinically-relevant QT-prolonging
effects, yielded false positives on hERG screening.
Given this tool’s inadequacies, one could imagine that
a screen utilizing hiPSC-CMs would perform better.
Indeed, using MEA technology, Navarette et al. (70)
demonstrated improved accuracy of an hiPSC-CM
screening system over traditional hERG screening.
They showed that hiPSC-CMs treatedwithmedications
known to cause QT prolongation recorded a compara-
ble response to hERG screening. However, unlike
hERG screening, their hiPSC-CM system predicted
the correct clinical response to alfuzosin and verap-
amil (70).
The hiPSCs may have a role for individualized drug
toxicity screening as well. Liang et al. (71) compared
single-cell recordings in hiPSC-CMs from patients
with LQTS and HCM to hESC-CMs and traditional
hERG screening. The LQTS and HCM hiPSC-CMs
treated with cisapride, a known QT-prolonging
agent, developed QT prolongation at lower doses
than control cells. This suggests hiPSC-CMs can be
used for individualized screening. As the production
of hiPSC-CMs becomes cheaper and faster, it may
eventually be feasible to screen high-risk patients
using assays derived completely from their own
cells (71).
Potentially, hiPSCs may improve development
of new therapeutics for inherited cardiac di-
seases, particularly by applying high-throughputtechnologies. With the continuing reﬁnement of
powerful computational software, we can now use
hiPSC-CMs to recreate a disease phenotype in vitro and
screen hundreds or thousands of novel and U.S. Food
and Drug Administration–approved compounds in just
hours or days. This technology may dramatically
improve the rate at which we discover new experi-
mental compounds (72).
CONCLUSIONS AND FUTURE DIRECTIONS
Although most existing hiPSC technology is not yet
ready for clinical translation, the studies that we
reviewed offer proof of concept that hiPSCs can
generate disease-speciﬁc CMs that respond in physio-
logically meaningful ways to drug treatment. As
differentiation protocols and high-throughput tech-
niques improve, hiPSC systems also may play an inte-
gral role in developing new pharmacologic agents for
genetically-based diseases and in screening com-
pounds for potential cardiotoxicities. Further re-
ﬁnements in these models are needed to produce
hiPSC-CMs that better replicate the physiology of
adult cells. Research is ongoing to develop differenti-
ation protocols that more faithfully mimic cardiac
embryogenesis, and laboratories are studying the use
of 3-dimensional structures, electrical pacing, and
mechanical strain to determine if these stimuli can
improve differentiation toward a more “adult-like”
state. Additionally, development of viable systems
that incorporate multiple cell types, noncell autono-
mous signaling events, and environmental factorsmay
allow the study of an even broader range of cardiac
diseases.
More than 30 years have passed since ESCs were
ﬁrst described, and many scientists have theorized
that this technology would transform cardiovascular
medicine. We ﬁrmly believe that the use of stem cells
as models for CVD will serve as a stepping stone to-
ward that transformation.
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